On March 14, 2023, Scitech Pharma announced that ST-1898 Tablets, the first anti-tumor targeted drug, discovered and designed by SigmaHit®, completed dosing of the first subject in Phase Ib/II clinical trial at Beijing Cancer Hospital.
ST-1898 Tablets received IND approval from National Medical Products Administration (NMPA) in July 2020. It is currently undergoing a Phase I dose-escalation clinical trial at Shanghai East Hospital, and has now completed all of the escalating doses specified in the clinical protocol. The trial drug has demonstrated different degrees of clinical benefit in all dose groups, with partial remission of tumor lesions observed in both high and low dose groups, and is safe and well tolerated. The purpose of this expanded clinical trial was to further evaluate the efficacy and safety of ST-1898 Tablets in patients with advanced renal cell carcinoma.
According to the Global New Cancer Statistics 2020, there are approximately 430,000 new cases of renal cancer worldwide. Currently, the main therapeutic agents for renal cancer include immunotherapeutic agents, anti-angiogenic agents, and mTOR inhibitors, with limited therapeutic choices, and there is still a huge unmet clinical need in the clinic. It is expected that ST-1898 will obtain positive clinical results and provide new treatment options for kidney cancer patients.
About ST-1898 Tablets
ST-1898, the first trial drug to enter clinical development phase, is a small molecule multi-target tyrosine kinase inhibitor developed via SigmaHit®, a proprietary AI drug design platform with global intellectual property rights, capable of inhibiting c-MET, VEGFR-2, PDGFRa, RET, c-KIT, TRK-A, TRK-B, AXL and other targets. Through the targeted design of multiple targets, the test drug can highly inhibit targets related to tumor development, progression and metastasis, thereby inhibiting multiple signaling pathways, directly and indirectly inhibiting tumor cell growth and migration, promoting apoptosis, and inhibiting tumor growth and metastasis through a combination of actions and synergistic mechanisms. Currently, Scitech Pharma is cooperating with Beijing Cancer Hospital to carry out translational medicine research on ST-1898, and will promote clinical research on more indications in the future.
Scitech Pharma
